SpyGlass Pharma Statistics
Total Valuation
SpyGlass Pharma has a market cap or net worth of $625.08 million. The enterprise value is $519.22 million.
| Market Cap | 625.08M |
| Enterprise Value | 519.22M |
Important Dates
The last earnings date was Thursday, May 14, 2026, after market close.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SpyGlass Pharma has 33.43 million shares outstanding.
| Current Share Class | 33.43M |
| Shares Outstanding | 33.43M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +19.38% |
| Owned by Insiders (%) | 4.28% |
| Owned by Institutions (%) | 15.99% |
| Float | 6.48M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.91 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.67, with a Debt / Equity ratio of 0.01.
| Current Ratio | 12.67 |
| Quick Ratio | 12.57 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -67.71% and return on invested capital (ROIC) is -42.04%.
| Return on Equity (ROE) | -67.71% |
| Return on Assets (ROA) | -37.23% |
| Return on Invested Capital (ROIC) | -42.04% |
| Return on Capital Employed (ROCE) | -38.64% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$613,369 |
| Employee Count | 65 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 21.80 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 43.05 |
| Average Volume (20 Days) | 75,333 |
Short Selling Information
The latest short interest is 1.14 million, so 3.42% of the outstanding shares have been sold short.
| Short Interest | 1.14M |
| Short Previous Month | 858,550 |
| Short % of Shares Out | 3.42% |
| Short % of Float | 17.67% |
| Short Ratio (days to cover) | 18.94 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -41.45M |
| Pretax Income | -39.87M |
| Net Income | -39.87M |
| EBITDA | -40.84M |
| EBIT | -41.45M |
| Earnings Per Share (EPS) | -$17.98 |
Balance Sheet
The company has $107.44 million in cash and $1.58 million in debt, with a net cash position of $105.85 million or $3.17 per share.
| Cash & Cash Equivalents | 107.44M |
| Total Debt | 1.58M |
| Net Cash | 105.85M |
| Net Cash Per Share | $3.17 |
| Equity (Book Value) | 105.70M |
| Book Value Per Share | -44.85 |
| Working Capital | 100.18M |
Cash Flow
In the last 12 months, operating cash flow was -$32.70 million and capital expenditures -$789,000, giving a free cash flow of -$33.49 million.
| Operating Cash Flow | -32.70M |
| Capital Expenditures | -789,000 |
| Depreciation & Amortization | 612,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -33.49M |
| FCF Per Share | -$1.00 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SpyGlass Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -6.38% |
| FCF Yield | -5.36% |
Analyst Forecast
The average price target for SpyGlass Pharma is $45.00, which is 140.64% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $45.00 |
| Price Target Difference | 140.64% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |